NCT05955456 Detecting EARLY Heart Failure in Greater Manchester
| NCT ID | NCT05955456 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Manchester University NHS Foundation Trust |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-10-09 |
| Primary Completion | 2030-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2023-10-09 with a primary completion date of 2030-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure represents a growing public health problem within the UK and particularly within the North West of England. A major challenge is that heart failure is currently diagnosed too late. The researchers have previously developed a risk calculator that accurately identifies individuals at risk of heart failure admission or death before they have developed heart failure. Most risk calculators are never implemented into clinical practice. The researchers will l perform a pilot study to evaluate the risk calculator within primary care in Greater Manchester.
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Aged 50 and over * Two or more of the following conditions: type 2 diabetes, chronic obstructive pulmonary disease, ischaemic heart disease, atrial fibrillation, hypertension, chronic kidney disease stage 3, body mass index ≥ 30 kg/m2 Exclusion Criteria: * Established diagnosis of one or more of the following: heart failure, cardiomyopathy, moderate or severe valvular heart disease, congenital heart disease, heart transplant, idiopathic, heritable or drug-induced pulmonary arterial hypertension, any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study. * Contraindication to cardiovascular magnetic resonance (CMR) scanning, including pacemaker, defibrillator, intraocular metal, intracranial aneurysm clips, severe claustrophobia, estimated glomerular filtration rate \< 30 ml/min/1.73m2, previous severe allergic reaction or anaphylaxis to gadolinium-based contrast agent, pregnancy or breastfeeding.
Frequently Asked Questions
Who can join the NCT05955456 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05955456 currently recruiting?
Yes, NCT05955456 is actively recruiting participants. Visit ClinicalTrials.gov or contact Manchester University NHS Foundation Trust to inquire about joining.
Where is the NCT05955456 trial being conducted?
This trial is being conducted at Manchester, United Kingdom.
Who is sponsoring the NCT05955456 clinical trial?
NCT05955456 is sponsored by Manchester University NHS Foundation Trust. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.